glp 1 types of drugs Market Overview: GLP-1 Agonists and the Obesity Market | Blog What to know about the
Description
Despite demonstrating robust glycemic efficacy, both agents were eventually discontinued due to distinct tolerability and safety concerns, diverging in severity and clinical implications
August 15, 2022
Conflict of interest The authors declare no conflict of interest Authors contributions Conceptualization, formal analysis, original draft preparation (SKC), writingreview and editing (SKC, DC), supervision, project administration, and funding acquisition (SKC)
Developed by Altimmune
Endocrinology 160 , 24172426 (2019)
Abstract Chronic treatment with GLP-1R agonists may moderately lower blood pressure due to increased natriuresis and RAAS inhibition
